The occasion highlighted leadership in vaccine progression and regional expansion in biotechnological innovation.
Today, Maryland Gov. Larry Hogan and Dr. Michelle McMurry-Heath, president and ceo of the Biotech Innovation Organization (BIO), joined Novavax President and CEO Stanley Erck in discussing the importance of the biotechnology sector in Maryland, industry efforts to fight COVID-19, and Novavax’s progress in creating a vaccine. A video of the comments is now available.
This multimedia press release. See the full edition here: https://www. businesswire. com/news/home/20200924005894/fr/
From left to right, Stanley Erck, CEO of Novavax, Larry Hogan, CEO of BIO, Dr. Michelle McMurry-Heath, CEO of BIO (Photo: Business Wire)
“When the COVID-19 crisis began, even before we had our first cases shown, I said that our state housed some of the most productive fitness studio amenities in the world, and I hoped we could participate in the progression of remedies and perhaps even a vaccine that opposes this fatal virus,” Governor Hogan said. Novavax took on this challenge and promptly took over. The state of Maryland is proud of Novavax’s efforts and our entire life sciences business group, which is at the forefront of combat opposing COVID-19. “
Dr. Michelle McMurry-Heath spoke about the biotechnology industry’s unprecedented reaction to COVID-19. “Novavax is a shining example of this reaction, this galvanized intellectual ability, and the ability to harness the strength of science to heal the world,” he said. “At the Biotechnology Innovation Organization, we couldn’t be more proud of how our companies, our scientists, our entrepreneurs, mobilized to replace the world. “
“We are about to enter another 3 Phase 3 trials, adding a trial that will begin within a time in the UK in another 10,000 people, a trial that will begin in the US. But it’s not the first time In a few weeks and it will involve another 30,000 people and a third phase 3 trial in India. We have a global presence. It’s a global disease. I don’t think it’s enough that we have a vaccine that’s only used for the United States. To protect America, you’ll have to shield the world. A global economy. And that’s what we’re doing, ” said Erck. “We feel a huge duty in our role at the forefront of vaccine progression and in our project to provide a safe and effective vaccine as temporarily as you can imagine to help combat the COVID-19 pandemic. As a clinical organization committed to improving health, it has been rewarding to see many like-minded actors in our region come together to do so. “
Comments were made at the site of the events at Novavax in Gaithersburg, Maryland. The full video of the comments can be obtained here.
About BIO
BIO is the world’s largest professional agreement representing biotechnology companies, educational institutions, state biotechnology centers and similar organizations in the United States and more than 30 countries. BIO members are interested in the studies and progression of cutting-edge biotech products in the fields of health. , agriculture, industry and the environment. BIO also organizes the BIO International Convention, the largest collection of the world’s biotech industry, as well as meetings of leading investors and partners around the world.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a complex biogeneration company that promotes global fitness through the discovery, progression and marketing of cutting-edge vaccines to prevent serious infectious diseases. Novavax is in clinical trials with NVX-CoV2373, its candidate vaccine for SARS-CoV-2, the culprit COVID-19 virus, NanoFlu ™, its tetravalent influenza vaccine, has achieved all the main objectives of its fundamental phase 3 clinical trial in the elderly. Both candidate vaccines incorporate Novavax-M’s patented saponin-based matrix ™ adjuvant for immune reaction and season the highest levels of neutralizing antibodies. Novavax is one of the leading innovators of recombinant vaccines; its patented recombination generation platform combines the strength and speed of genetic engineering to successfully produce superior immunogenic nanoparticles to meet the urgent needs of global fitness.
About NVX-CoV2373
NVX-CoV2373 is a candidate vaccine designed from the genetic series of SARS-CoV-2, the virus responsible for the COVID-19 disease. NVX-CoV2373 was created using Novavax’s generation of recombinant nanoparticles to generate an antigen derived from the coronavirus spike protein (S) and comprises Novavax’s proprietary saponin-based Matrix-M ™ adjuvant for immune reaction and stimulating peak levels of neutralizing antibodies. NVX-CoV2373 comprises purified protein antigens and cannot replicate or cause COVID-19. In preclinical trials, NVX-CoV2373 has shown an indication of antibodies that block the binding of the spike protein to targeted receptors throughout the virus, a critical facet for effective protection of the vaccine. In its Phase 1 portion of its Phase 1/2 clinical trial, NVX-CoV2373 was sometimes well tolerated and elicited physically powerful antibody reactions that were numerically staggering to those seen in human convalescent sera. NVX-CoV2373 is also being evaluated in two ongoing phase 2 studies, which began in August; a phase 2b trial in South Africa and a continuation of phase 1/2 in the United States and Australia. Novavax has secured a $ 2 billion investment for its global coronavirus vaccine program, adding up to $ 388 million in investment from the Coalition for Innovations in Epidemic Preparedness (CEPI).
About Matrix-M ™
Novavax’s patented Matrix-M ™ adjuvant demonstrated a strong and well-tolerated effect by stimulating antigen-presenting cells’ access to the injection site and the presentation of antigens in local lymph nodes, stimulating immune response.
Novavax Forward-Looking Statements
Statements made in this document regarding Novavax’s long term and continued progress of its vaccines and adjuvants are forward-looking statements. Novavax cautions that these forward-looking statements are subject to dangers and uncertainties, which may cause the actual effects to differ materially from those expressed or implied in those statements. These dangers and uncertainties come with those known under the heading “Risk Factors” in Novavax’s annual report on shape 10-K for the year ended December 31, 2019 and in the quarterly report on shape 8-K for the era. which ended December 30, 2019. June 2020, as filed with the Securities and Exchange Commission (SEC). Investors are cautioned not to place significant reliance on the forward-looking statements contained in this press release. We inspire you to read our SEC filings, available at sec. gov, for a discussion of these and other dangers and uncertainties. The forward-looking statements contained in this press release refer only to the date of this document, and we do not assume any legal responsibility to update or revise such statements. Our business is subject to significant dangers and uncertainties, in addition to those mentioned above. Investors, potential investors, and others deserve to carefully consider these dangers and uncertainties.
See the edition in businesswire. com: https://www. businesswire. com/news/home/20200924005894/fr/
contacts
BIO Media Theresa Bradytbrady@bio. org
For information, please visit: https://www. bio. org/ us on Twitter – IAmBiotech Find Us on LinkedIn
Novavax investors Silvia Taylor and Erika Trahanir@novavax. com 240-268-2022
Brandzone Media / KOGS Communication Edna Kaplankaplan@kogspr. com 617-974-8659
For more information, visit www. novavax. com and join us on Twitter and LinkedIn.